Squadra Avocats supports GRAFTYS and BIOLOGICS 4 LIFE in their insolvency proceedings 26/06/24

Squadra (Charles Morel et Emilie Rosier) has recently supported the companies GRAFTYS and BIOLOGICS 4 LIFE in their insolvency proceedings before the Aix-en-Provence Commercial Court.

Graftys specialises in the development of bioresorbable synthetic bone grafts for orthopedic surgery. After carrying out research on biomaterials, the company created a new type of synthetic bone graft, that can be easily injected into the centre of bones in order to repair them. Graftys is now a market leader and has received particular recognition for its work in the US.

In 2021, it acquired another French medtech company, Biologics 4 Life, working in a similar field: the development of injectable biomaterials combined with active ingredients capable of treating and preventing fractures caused by osteoporosis.

Due to a now-resolved regulatory constraint., Graftys had to suspend activity for a number of months in 2023. Faced with financial difficulties at the beginning of 2024, it was necessary for the companies to enter into insolvency proceedings.